Immunotherapy in Melanoma Articles

Adjuvant Pembrolizumab Improves RFS in Melanoma
Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.
FDA Approves Adjuvant Nivolumab for Melanoma
The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Immunotherapy Resistance Remains a Puzzle
Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.
Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.
NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
Adjuvant Nivolumab/Ipilimumab Sustains RFS Benefit in Melanoma at 3 Years
The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.
Nivolumab/Ipilimumab Combo Active for Melanoma Brain Mets
The combination of nivolumab and ipilimumab showed an intracranial response rate of 46% for asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Triplet Therapy on Horizon for BRAF+ Melanoma
The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with BRAF-mutant advanced melanoma.
Novel Combinations Mark Next Step for Melanoma
Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.
Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma
Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.
Publication Bottom Border
Border Publication